Sivaramakrishna P Rachakonda1, Olaf Penack1, Sascha Dietrich1, Olga Blau1, Igor Wolfgang Blau1, Aleksandar Radujkovic1, Berend Isermann1, Anthony D Ho1, Lutz Uharek1, Peter Dreger1, Rajiv Kumar1, Thomas Luft2. 1. Sivaramakrishna P. Rachakonda and Rajiv Kumar, German Cancer Research Centre; Sascha Dietrich, Aleksandar Radujkovic, Anthony D. Ho, Peter Dreger, and Thomas Luft, University of Heidelberg, Heidelberg; Olaf Penack, Olga Blau, Igor Wolfgang Blau, and Lutz Uharek, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin; and Berend Isermann, Otto-von-Guericke University Magdeburg, Magdeburg, Germany. 2. Sivaramakrishna P. Rachakonda and Rajiv Kumar, German Cancer Research Centre; Sascha Dietrich, Aleksandar Radujkovic, Anthony D. Ho, Peter Dreger, and Thomas Luft, University of Heidelberg, Heidelberg; Olaf Penack, Olga Blau, Igor Wolfgang Blau, and Lutz Uharek, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin; and Berend Isermann, Otto-von-Guericke University Magdeburg, Magdeburg, Germany. thomas.luft@med.uni-heidelberg.de.
Abstract
PURPOSE: Steroid-refractory graft-versus-host disease (GVHD) is a major and often fatal complication after allogeneic stem-cell transplantation (alloSCT). Although the pathophysiology of steroid refractoriness is not fully understood, evidence is accumulating that endothelial cell stress is involved, and endothelial thrombomodulin (THBD) plays a role in this process. Here we assess whether single-nucleotide polymorphisms (SNPs) within the THBD gene predict outcome after alloSCT. PATIENTS AND METHODS: Seven SNPs within the THBD gene were studied (rs1962, rs1042579, rs1042580, rs3176123, rs3176124, rs3176126, and rs3176134) in a training cohort of 306 patients. The relevant genotypes were then validated in an independent cohort (n = 321). RESULTS: In the training cohort, an increased risk of nonrelapse mortality (NRM) was associated with three of seven SNPs tested: rs1962, rs1042579 (in linkage disequilibrium with rs3176123), and rs1042580. When patients were divided into risk groups (one v no high-risk SNP), a strong correlation with NRM was observed (hazard ratio [HR], 2.31; 95% CI, 1.36 to 3.95; P = .002). More specifically, NRM was predicted by THBD SNPs in patients who later developed GVHD (HR, 3.03; 95% CI, 1.61 to 5.68; P < .001) but not in patients without GVHD. In contrast, THBD SNPs did not predict incidence of acute GVHD. Multivariable analyses adjusting for clinical variables confirmed the independent effect of THBD SNPs on NRM. All findings could be reproduced in the validation cohort. CONCLUSION: THBD SNPs predict mortality of manifest GVHD but not the risk of acquiring GVHD, supporting the hypothesis that endothelial vulnerability contributes to GVHD refractoriness.
PURPOSE:Steroid-refractory graft-versus-host disease (GVHD) is a major and often fatal complication after allogeneic stem-cell transplantation (alloSCT). Although the pathophysiology of steroid refractoriness is not fully understood, evidence is accumulating that endothelial cell stress is involved, and endothelial thrombomodulin (THBD) plays a role in this process. Here we assess whether single-nucleotide polymorphisms (SNPs) within the THBD gene predict outcome after alloSCT. PATIENTS AND METHODS: Seven SNPs within the THBD gene were studied (rs1962, rs1042579, rs1042580, rs3176123, rs3176124, rs3176126, and rs3176134) in a training cohort of 306 patients. The relevant genotypes were then validated in an independent cohort (n = 321). RESULTS: In the training cohort, an increased risk of nonrelapse mortality (NRM) was associated with three of seven SNPs tested: rs1962, rs1042579 (in linkage disequilibrium with rs3176123), and rs1042580. When patients were divided into risk groups (one v no high-risk SNP), a strong correlation with NRM was observed (hazard ratio [HR], 2.31; 95% CI, 1.36 to 3.95; P = .002). More specifically, NRM was predicted by THBD SNPs in patients who later developed GVHD (HR, 3.03; 95% CI, 1.61 to 5.68; P < .001) but not in patients without GVHD. In contrast, THBD SNPs did not predict incidence of acute GVHD. Multivariable analyses adjusting for clinical variables confirmed the independent effect of THBD SNPs on NRM. All findings could be reproduced in the validation cohort. CONCLUSION:THBD SNPs predict mortality of manifest GVHD but not the risk of acquiring GVHD, supporting the hypothesis that endothelial vulnerability contributes to GVHD refractoriness.
Authors: Shernan G Holtan; Michael R Verneris; Kirk R Schultz; Laura F Newell; Gabrielle Meyers; Fiona He; Todd E DeFor; Gregory M Vercellotti; Arne Slungaard; Margaret L MacMillan; Sarah A Cooley; Bruce R Blazar; Angela Panoskaltsis-Mortari; Daniel J Weisdorf Journal: Biol Blood Marrow Transplant Date: 2015-03-07 Impact factor: 5.742
Authors: Ezgi Karaesmen; Abbas A Rizvi; Leah M Preus; Philip L McCarthy; Marcelo C Pasquini; Kenan Onel; Xiaochun Zhu; Stephen Spellman; Christopher A Haiman; Daniel O Stram; Loreall Pooler; Xin Sheng; Qianqian Zhu; Li Yan; Qian Liu; Qiang Hu; Amy Webb; Guy Brock; Alyssa I Clay-Gilmour; Sebastiano Battaglia; David Tritchler; Song Liu; Theresa Hahn; Lara E Sucheston-Campbell Journal: Blood Date: 2017-08-15 Impact factor: 22.113
Authors: E Mir; M Palomo; M Rovira; A Pereira; G Escolar; O Penack; E Holler; E Carreras; M Diaz-Ricart Journal: Bone Marrow Transplant Date: 2017-06-26 Impact factor: 5.483
Authors: M Zeisbrich; N Becker; A Benner; A Radujkovic; K Schmitt; J Beimler; A D Ho; M Zeier; P Dreger; T Luft Journal: Bone Marrow Transplant Date: 2017-06-26 Impact factor: 5.483
Authors: Carolina Martínez-Laperche; Elena Buces; M Carmen Aguilera-Morillo; Antoni Picornell; Milagros González-Rivera; Rosa Lillo; Nazly Santos; Beatriz Martín-Antonio; Vicent Guillem; José B Nieto; Marcos González; Rafael de la Cámara; Salut Brunet; Antonio Jiménez-Velasco; Ildefonso Espigado; Carlos Vallejo; Antonia Sampol; José María Bellón; David Serrano; Mi Kwon; Jorge Gayoso; Pascual Balsalobre; Álvaro Urbano-Izpizua; Carlos Solano; David Gallardo; José Luis Díez-Martín; Juan Romo; Ismael Buño Journal: Blood Adv Date: 2018-07-24
Authors: Sonata Jodele; Tsuyoshi Fukuda; Kana Mizuno; Alexander A Vinks; Benjamin L Laskin; Jens Goebel; Bradley P Dixon; Ranjit S Chima; Russel Hirsch; Ashley Teusink; Danielle Lazear; Adam Lane; Kasiani C Myers; Christopher E Dandoy; Stella M Davies Journal: Biol Blood Marrow Transplant Date: 2015-10-09 Impact factor: 5.742
Authors: Laura F Newell; Todd E DeFor; Corey Cutler; Michael R Verneris; Bruce R Blazar; Jeff S Miller; Joseph H Antin; Alan Howard; Juan Wu; Margaret L MacMillan; Angela Panoskaltsis-Mortari; Daniel J Weisdorf; Shernan G Holtan Journal: Biol Blood Marrow Transplant Date: 2019-11-10 Impact factor: 5.742